High HCV Cure Rates in HIV Coinfection Cases at Urban Clinic
Sustained virologic response rate of 97 percent, with no variation by race in predominantly black cohort
THURSDAY, June 15, 2017 (HealthDay News) -- For patients in an urban clinic with hepatitis C virus (HCV) with HIV coinfection, HCV treatment is effective with standardized nurse/pharmacist support, according to a study published online June 13 in Hepatology.
Oluwaseun Falade-Nwulia, M.B.B.S., M.P.H., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues examined HCV treatment outcomes among 255 HCV coinfected patients (88 percent black) initiating direct-acting antivirals between February 2014 and March 2016 in an urban clinic. Patients received standardized HIV nurse/pharmacist support, which included telephone calls and nurse visits.
The researchers found that 60 percent of participants had significant fibrosis and 30 percent had received treatment for HCV. Ninety-one percent of patients received ledipasvir/sofosbuvir with or without ribavirin and received 12 weeks of treatment. The sustained virologic response rate was 97 percent, with no variation by race (black and non-black, 96 and 97 percent, respectively), history of drug use, alcohol use, or psychiatric diagnosis.
"HCV treatment was highly effective among HIV-infected patients who received care within an integrated nurse/pharmacist adherence support program," the authors write. "These results suggest that race and psychosocial comorbidity may not be barriers to HCV elimination."